医疗器械公司Inari Medical, Inc. (NARI)2024年第三季度财报数据超出分析师预期,推动其股价在盘前大涨8.06%。
具体来看,Inari Medical第三季度调整后每股亏损为9美分,优于预期的11美分亏损,营收同比增长21.4%至1.5339亿美元,也高于市场预期水平。
虽然该公司仍处于亏损状态,但良好的业绩数据和持续高速增长使其获得市场认可。目前分析师给予Inari Medical一致的"买入"评级,看好其在医疗器械领域的长期成长空间。未来几个季度业绩持续超预期可期,有望进一步推动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.